



## Molecular Research on Non-small Cell Lung Cancer

Guest Editor:

### Dr. Chuhee Lee

Department of Biochemistry and  
Molecular Biology, School of  
Medicine, 170 Hyun-Chung Ro,  
Yeungnam University, Daegu  
42415, Republic of Korea

Deadline for manuscript  
submissions:

**closed (30 April 2022)**

### Message from the Guest Editor

This Special Issue focuses on “Molecular Research on Non-Small Cell Lung Cancer”. Recently, various oncogenes have been found to be overexpressed in NSCLC and highly correlated with aggressiveness, epithelial-to-mesenchymal transition, and chemoresistance, since they transduce multiple signals for cell growth, survival, proliferation, invasion, migration, angiogenesis, and inhibition of apoptosis. Therefore, customized therapy targeting these oncogenes may be a potent and practical target for the successful treatment of NSCLC, and this will be the focus of this Special Issue. Review manuscripts as well as original investigations demonstrating novel therapeutic targets and candidates to be tested in clinical trials and the underlying molecular mechanisms and crosstalk of signaling with other signaling pathways will be considered for publication.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI